2023
Standardized Clinical Pathways Improve Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department
Forward J, Thomas D, O'Malley S, Berkwitt A, Calhoun C, Krishnamurti L, Pashankar F. Standardized Clinical Pathways Improve Management of Vaso-Occlusive Episodes in the Pediatric Emergency Department. Blood 2023, 142: 2315. DOI: 10.1182/blood-2023-181285.Peer-Reviewed Original ResearchVaso-occlusive episodesSickle cell diseasePediatric emergency departmentMinutes of arrivalPain managementEmergency departmentClinical pathwayIntranasal fentanylYears post implementationHydromorphone PCAPain medicationPediatric patientsJune 30 thPain medication administrationVaso-occlusive painPercent of patientsPercentage of patientsQuality improvement projectOutcome one yearElectronic medical recordsPost implementationHealth care systemFirst analgesicED visitsED encountersAllotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States
Goshua G, Ito S, Chetlapalli K, Potnis K, Calhoun C, Krishnamurti L, Krumholz H, Pandya A. Allotransplantation and Gene Therapy Equity for Children with Sickle Cell Disease: Distributional Cost-Effectiveness of Allotransplantation Vs Gene Therapy Vs Standard-of-Care in Pediatric Patients with Sickle Cell Disease in the United States. Blood 2023, 142: 490. DOI: 10.1182/blood-2023-191072.Peer-Reviewed Original ResearchSickle cell diseaseIncremental cost-effectiveness ratioDistributional cost-effectiveness analysisPediatric patientsCell diseaseCost-effectiveness analysisDisease severityHealth resource utilization dataPediatric Health Information SystemGene therapyJustifiable treatment optionTransplant-related mortalityVaso-occlusive crisisExpert clinical experienceMarrow Transplant ResearchSubstantial mortality riskVisual analog scaleQuality-adjusted life expectancyConcomitant riskCost-effectiveness ratioResource utilization dataCost-effectiveness frontierHost diseaseMaximum patientsOpioid therapy
2021
386 Cryptogenic Organizing Pneumonia Following HLA Identical Hematopoietic Stem Cell Transplantation for Sickle Cell Disease: A Case Series of Three Pediatric Patients
Bauchat A, Williams K, Simon D, Parikh S, Krishnamurti L. 386 Cryptogenic Organizing Pneumonia Following HLA Identical Hematopoietic Stem Cell Transplantation for Sickle Cell Disease: A Case Series of Three Pediatric Patients. Transplantation And Cellular Therapy 2021, 27: s321-s322. DOI: 10.1016/s2666-6367(21)00412-7.Peer-Reviewed Original Research
2019
Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial
Krishnamurti L, Ross D, Sinha C, Leong T, Bakshi N, Mittal N, Veludhandi D, Pham A, Taneja A, Gupta K, Nwanze J, Matthews A, Joshi S, Olivieri V, Arjunan S, Okonkwo I, Lukombo I, Lane P, Bakshi N, Loewenstein G. Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial. Journal Of Medical Internet Research 2019, 21: e14462. PMID: 31799940, PMCID: PMC6934048, DOI: 10.2196/14462.Peer-Reviewed Original ResearchConceptsRandomized clinical trialsPatient decision aidSickle cell diseaseWeb-based patient decision aidClinical trialsHealth care providersCell diseaseDecisional conflictPatient knowledgeCare providersDecision aid armStandard care armOttawa Decision Support FrameworkChronic blood transfusionsDisease-modifying therapiesBone marrow transplantationDecision aidCare armDecision aid prototypeClinical characteristicsBlood transfusionControlled TrialsPediatric patientsMarrow transplantationTherapeutic options
2018
Administration of BPX-501 Cells Following Aβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias
Locatelli F, Ruggeri A, Merli P, Naik S, Agarwal R, Aquino V, Jacobsohn D, Qasim W, Nemecek E, Krishnamurti L, Manwani D, Kuhn M, Kapoor N. Administration of BPX-501 Cells Following Aβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias. Blood 2018, 132: 307. DOI: 10.1182/blood-2018-99-119481.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationRelapse-free survivalHLA-haploidentical hematopoietic stem cell transplantationEfficacy-evaluable populationHaplo-HSCTComplete remissionOverall survivalAcute leukemiaΑβ TB cellsEvaluable patientsPediatric patientsT cellsLower riskUnrelated donor hematopoietic stem cell transplantationDonor hematopoietic stem cell transplantationHaploidentical hematopoietic stem cell transplantationAllogeneic hematopoietic stem cell transplantationBetter overall clinical responseSteroid-resistant acute GVHDConventional steroid therapyOverall clinical responseSteroid-resistant GVHDTransplant-related mortalityPrimary graft failureAdministration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-Versus-Host-Disease (GvHD)
Elkeky R, Jacobsohn D, Agarwal R, Naik S, Kapoor N, Krishnamurti L, Slatter M, Galaverna F, Merli P, Aldinger M, Locatelli F. Administration of Rimiducid Following Haploidentical BPX-501 Cells in Children with Malignant or Non-Malignant Disorders Who Develop Graft-Versus-Host-Disease (GvHD). Blood 2018, 132: 2207. DOI: 10.1182/blood-2018-99-119792.Peer-Reviewed Original ResearchNon-malignant disordersHematopoietic stem cell transplantationTreatment of GVHDDonor T cellsΑβ T cellsT cellsHaplo-HSCTImmune recoveryAdoptive transferPediatric patientsMedian timeB cellsAllogeneic hematopoietic stem cell transplantationOverall clinical response rateConventional steroid therapyEfficacy-evaluable populationOnset of GVHDSteroid-refractory GVHDClinical response rateHLA-compatible donorsStem cell transplantStem cell transplantationΑβ T cell receptorAdvisory CommitteeEffective treatment approachPain catastrophizing is associated with poorer health-related quality of life in pediatric patients with sickle cell disease
Bakshi N, Lukombo I, Belfer I, Krishnamurti L. Pain catastrophizing is associated with poorer health-related quality of life in pediatric patients with sickle cell disease. Journal Of Pain Research 2018, 11: 947-953. PMID: 29773954, PMCID: PMC5947835, DOI: 10.2147/jpr.s151198.Peer-Reviewed Original ResearchSickle cell diseasePoor health-related qualityHealth-related qualityHealth care utilizationPoor HRQOLPain intensityCare utilizationCell diseaseDepressive symptomsPrior health care utilizationPsychological factorsPain-related outcomesRace-matched controlsCross-sectional studyQuality of lifePaucity of dataSCD outcomesPain burdenPediatric patientsRed blood cellsPain interferenceMultisystem involvementPain phenotypingHRQoLPsychological covariatesQuantitative sensory testing is feasible and is well-tolerated in patients with sickle cell disease following a vaso-occlusive episode
Bakshi N, Lukombo I, Belfer I, Krishnamurti L. Quantitative sensory testing is feasible and is well-tolerated in patients with sickle cell disease following a vaso-occlusive episode. Journal Of Pain Research 2018, 11: 435-443. PMID: 29503580, PMCID: PMC5827673, DOI: 10.2147/jpr.s150066.Peer-Reviewed Original ResearchVaso-occlusive episodesQuantitative sensory testingSickle cell diseaseChronic painPain sensitivityCell diseaseSensory testingPainful vaso-occlusive episodesExperience chronic painFeasibility of recruitmentLarge prospective studiesEmergency room visitsExperimental pain sensitivityInherited blood disorderAltered painMedian agePain intensityPediatric patientsRoom visitsProspective studyInpatient hospitalizationSubset of individualsPainPatientsBlood disorders
2017
Psychological Characteristics and Pain Frequency Are Associated With Experimental Pain Sensitivity in Pediatric Patients With Sickle Cell Disease
Bakshi N, Lukombo I, Shnol H, Belfer I, Krishnamurti L. Psychological Characteristics and Pain Frequency Are Associated With Experimental Pain Sensitivity in Pediatric Patients With Sickle Cell Disease. Journal Of Pain 2017, 18: 1216-1228. PMID: 28602692, DOI: 10.1016/j.jpain.2017.05.005.Peer-Reviewed Original ResearchConceptsSickle cell diseaseExperimental pain stimuliExperimental pain sensitivityPain sensitivityPain stimuliChronic painExperimental painCell diseasePsychological characteristicsQuantitative sensory testing methodsPsychological factorsChronic SCD painMechanical temporal summationVaso-occlusive painQuantitative sensory testingSubset of patientsPain-related outcomesStudy of patientsCross-sectional assessmentChildren ages 8SCD painPain burdenPain frequencyPediatric patientsPain processing
2016
Gonadal shielding technique to preserve fertility in male pediatric patients treated with total body irradiation for stem cell transplantation
Sayan M, Cassidy R, Butker E, Nanda R, Krishnamurti L, Khan M, Esiashvili N. Gonadal shielding technique to preserve fertility in male pediatric patients treated with total body irradiation for stem cell transplantation. Bone Marrow Transplantation 2016, 51: 997-998. PMID: 26950374, DOI: 10.1038/bmt.2016.25.Peer-Reviewed Original Research
2015
A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children
Brousseau D, Scott J, Badaki-Makun O, Darbari D, Chumpitazi C, Airewele G, Ellison A, Smith-Whitley K, Mahajan P, Sarnaik S, Casper T, Cook L, Dean J, Leonard J, Hulbert M, Powell E, Liem R, Hickey R, Krishnamurti L, Hillery C, Nimmer M, Panepinto J, Network F. A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children. Blood 2015, 126: 1651-1657. PMID: 26232172, PMCID: PMC4591790, DOI: 10.1182/blood-2015-05-647107.Peer-Reviewed Original ResearchConceptsSickle cell pain crisisLength of stayPediatric Emergency Care Applied Research NetworkPain crisisIntravenous magnesiumOpioid useNormal saline placeboStudy drug infusionPlacebo-controlled trialHealth-related qualityQuality of lifeMorphine equivalentsStudy drugSaline placeboSecondary outcomesStandard therapyHemoglobin SSPediatric patientsPrimary outcomeDrug infusionPain relieversPlaceboStayChildren 4Group demographics
2014
Does e-pain plan improve management of sickle cell disease associated vaso-occlusive pain crisis? A mixed methods evaluation
Kato-Lin Y, Krishnamurti L, Padman R, Seltman H. Does e-pain plan improve management of sickle cell disease associated vaso-occlusive pain crisis? A mixed methods evaluation. International Journal Of Medical Informatics 2014, 83: 814-824. PMID: 25179666, DOI: 10.1016/j.ijmedinf.2014.08.003.Peer-Reviewed Original ResearchConceptsVaso-occlusive pain crisesSickle cell diseasePain managementMixed-methods evaluationPain crisisEmergency departmentHealth information technologyCell diseaseInpatient unitSickle cell disease patientsIndividualized pain plansAnalgesic ordersPain planED visitsFirst dosePediatric patientsChildren's HospitalDisease patientsHigh baseline performanceClinicians insightNurses' perspectivesPatient recordsHealth information systemsSimple interventionCare qualityProdromal Illness Before Acute Chest Syndrome in Pediatric Patients With Sickle Cell Disease
Creary S, Krishnamurti L. Prodromal Illness Before Acute Chest Syndrome in Pediatric Patients With Sickle Cell Disease. Journal Of Pediatric Hematology/Oncology 2014, 36: 480-483. PMID: 24633302, DOI: 10.1097/mph.0000000000000146.Peer-Reviewed Original ResearchConceptsAcute chest syndromeSickle cell diseaseProdromal illnessCell diseaseChest syndromePainful vaso-occlusive crisesHistory of asthmaThird of patientsVaso-occlusive crisisICD-9-CMAcute visitsACS episodeChart reviewPediatric patientsPediatric hospitalHigh riskCommon reasonPatientsIllnessCareDiseaseVisitsSyndromeChildrenFurther researchA pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle‐cell disease
Creary S, Gladwin M, Byrne M, Hildesheim M, Krishnamurti L. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle‐cell disease. Pediatric Blood & Cancer 2014, 61: 1068-1073. PMID: 24436121, DOI: 10.1002/pbc.24931.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAnemia, Sickle CellAntisickling AgentsCell PhoneChildChild, PreschoolDirectly Observed TherapyDrug Administration ScheduleElectronic MailFeedbackFemaleHealth SurveysHumansHydroxyureaMaleMedication AdherenceMicrocomputersPatient SatisfactionPilot ProjectsReimbursement, IncentiveReminder SystemsRewardText MessagingVideo RecordingYoung AdultConceptsSickle cell diseaseMedian medication possession ratioMean corpuscular volumeHU adherenceHydroxyurea adherencePilot studyHemoglobin F percentageMedication possession ratioParticipant satisfactionPossession ratioSecondary outcomesPediatric patientsPrimary outcomeStudy entryClinical outcomesHU useHU therapyOverall participant satisfactionSingle institutionCell diseaseReminder alertsCorpuscular volumeTherapyAdherenceOverall median
2013
Is intensive monitoring during the first transfusion in pediatric patients necessary?
Berg A, Courtney R, Krishnamurti L, Triulzi D, Yazer M. Is intensive monitoring during the first transfusion in pediatric patients necessary? Hematology 2013, 19: 304-308. PMID: 24074624, DOI: 10.1179/1607845413y.0000000122.Peer-Reviewed Original ResearchConceptsIntensive care unitFirst transfusionPediatric patientsElectronic medical recordsTransfusion historyICU managementTertiary care pediatric hospitalPatient's transfusion historyPatients' electronic medical recordsList of patientsBlood bank recordsICU admissionRegular wardSubsequent transfusionsSignificant hypotensionCare unitPediatric hospitalAcute reactionsMedical recordsICU teamTransfusion reactionsBlood productsSevere reactionsTransfusionPatientsLong Term Safety and Efficacy Of Low Fixed Dose Hydroxyurea In Pediatric Patients With Sickle Cell Anemia: A Single Center Study From Central India
Jain D, Krishnamurti L, Sarathi V, Desai S, Gokhale A. Long Term Safety and Efficacy Of Low Fixed Dose Hydroxyurea In Pediatric Patients With Sickle Cell Anemia: A Single Center Study From Central India. Blood 2013, 122: 1000. DOI: 10.1182/blood.v122.21.1000.1000.Peer-Reviewed Original ResearchAcute chest syndromeSickle cell anemiaLong-term safetyChest syndromeLow-resource settingsPediatric patientsSevere anemiaHigh HbF levelsSCA patientsTerm safetyCell anemiaLong-term observational followSingle tertiary care centerResource settingsAvascular bone necrosisEvidence of neutropeniaHbF levelsSingle-center studyTertiary care centerAmelioration of diseaseMean corpuscular hemoglobin concentrationHIV/AIDSCorpuscular hemoglobin concentrationSequestration crisisMean hemoglobin
2007
Hematopoietic cell transplantation for sickle cell disease: state of the art
Krishnamurti L. Hematopoietic cell transplantation for sickle cell disease: state of the art. Expert Opinion On Biological Therapy 2007, 7: 161-172. PMID: 17250455, DOI: 10.1517/14712598.7.2.161.Peer-Reviewed Original ResearchConceptsHematopoietic cell transplantationSickle cell diseaseCell transplantationCell diseaseReduced-intensity conditioning regimenIndication of transplantationImpact of transplantationStem cell transplantationPossibility of cureEffect of treatmentConditioning regimenPreparative regimensPulmonary hypertensionBlood transfusionConsiderable morbidityPediatric patientsOrgan damagePremature mortalityTransplantationNatural historyMorbidityMortalityDiseaseStem cellsSafe useHEMATOPOIETIC CELL TRANSPLANTATION: A Curative Option for Sickle Cell Disease
Krishnamurti L. HEMATOPOIETIC CELL TRANSPLANTATION: A Curative Option for Sickle Cell Disease. Pediatric Hematology And Oncology 2007, 24: 569-575. PMID: 18092247, DOI: 10.1080/08880010701640531.Peer-Reviewed Original ResearchConceptsSickle cell diseaseCell transplantationCell diseaseReduced intensity conditioning regimenIndication of transplantationHematopoietic cell transplantationImpact of transplantationIntensity conditioning regimenStem cell transplantationPossibility of cureEffect of treatmentConditioning regimenPreparative regimenPulmonary hypertensionCurative optionBlood transfusionConsiderable morbidityPediatric patientsRelated morbidityOrgan damagePremature mortalityTransplantationNatural historyMorbidityRegimen
1999
#432 Danaparoid (orgaran) anti-coagulation of pediatric patients with heparin-induced thrombocytopenia (HIT)
Weigel B, Lasky A, Krishnamurti L, Perentesis J, Neglia J, Foker J, Key N, Edson R, Steiner M. #432 Danaparoid (orgaran) anti-coagulation of pediatric patients with heparin-induced thrombocytopenia (HIT). Journal Of Pediatric Hematology/Oncology 1999, 21: 457. DOI: 10.1097/00043426-199909000-00035.Peer-Reviewed Original Research#432 Danaparoid (orgaran) anticoagulation of pediatric patients with heparininduced thrombocytopenia (HIT)
Weigel B, Lasky A, Krishnamurti L, Perentesis J, Neglia J, Foker J, Key N, Edson R, Steiner M. #432 Danaparoid (orgaran) anticoagulation of pediatric patients with heparininduced thrombocytopenia (HIT). Journal Of Pediatric Hematology/Oncology 1999, 21: 327. DOI: 10.1097/00043426-199907000-00093.Peer-Reviewed Original Research